FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for FINTEPLA (fenfluramine) filed by UCB, Inc., expanding/adjusting its labeling and indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Epilepsy

Drugs mentioned

• Fintepla (Fenfluramine)

Snippet

SUPPL AP for FINTEPLA (FENFLURAMINE)